Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry

Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry

New carborane-bearing hydroxamate matrix metalloproteinase (MMP) ligands have been synthesized for boron neutron capture therapy (BNCT) with nanomolar potency against MMP-2, -9 and -13. New analogs are based on MMP inhibitor CGS-23023A, and two previously reported MMP ligands <b>1</b> (&...

Full description

Bibliographic Details
Main Authors: Sebastian Flieger, Mao Takagaki, Natsuko Kondo, Marlon R. Lutz, Yash Gupta, Hiroki Ueda, Yoshinori Sakurai, Graham Moran, Prakasha Kempaiah, Narayan Hosmane, Minoru Suzuki, Daniel P. Becker
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:International Journal of Molecular Sciences
Subjects:
boron neutron capture therapy
BNCT
matrix metalloproteinase
MMP
carborane
cancer
Online Access:https://www.mdpi.com/1422-0067/24/8/6973

Internet

https://www.mdpi.com/1422-0067/24/8/6973

Similar Items